Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals. The U.S. Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, abuse-deterrent products, liquids, semi-solids, patches, powders, ophthalmics, sprays, and sterile injectables, as well as products for the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular disease markets.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone011-353-1268-2000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.95 billion
Profitability
Miscellaneous
Employees2,910
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable
Endo International (NASDAQ:ENDP) Frequently Asked Questions
What is Endo International's stock symbol?
Endo International trades on the NASDAQ under the ticker symbol "ENDP."
How were Endo International's earnings last quarter?
Endo International PLC (NASDAQ:ENDP) posted its quarterly earnings results on Monday, November, 4th. The company reported $0.60 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.53 by $0.07. The business earned $729 million during the quarter, compared to analyst estimates of $709.01 million. Endo International had a negative net margin of 16.89% and a negative return on equity of 99.08%. The company's revenue was down 2.1% on a year-over-year basis. During the same period in the prior year, the business posted $0.71 earnings per share. View Endo International's Earnings History.
When is Endo International's next earnings date?
How can I listen to Endo International's earnings call?
Endo International will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for ENDP?
13 brokerages have issued 1 year target prices for Endo International's shares. Their forecasts range from $2.00 to $15.00. On average, they anticipate Endo International's stock price to reach $7.38 in the next twelve months. This suggests a possible upside of 21.5% from the stock's current price. View Analyst Price Targets for Endo International.
What is the consensus analysts' recommendation for Endo International?
13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Endo International in the last year. There are currently 2 sell ratings, 8 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Endo International.
Has Endo International been receiving favorable news coverage?
Media stories about ENDP stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Endo International earned a news sentiment score of 0.5 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Endo International.
Who are some of Endo International's key competitors?
Some companies that are related to Endo International include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Horizon Therapeutics (HZNP), Nektar Therapeutics (NKTR) and Pacira Biosciences (PCRX).
What other stocks do shareholders of Endo International own?
Who are Endo International's key executives?
Endo International's management team includes the folowing people:
- Mr. Paul V. Campanelli, Pres, CEO & Director (Age 57)
- Mr. Blaise Coleman, Exec. VP & CFO (Age 45)
- Mr. Terrance J. Coughlin, Exec. VP & COO (Age 53)
- Mr. Matthew Joseph Maletta, Exec. VP & Chief Legal Officer (Age 47)
- Mr. Antonio R. Pera, Pres of Par Pharmaceutical (Age 62)
Who are Endo International's major shareholders?
Endo International's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.41%), Bank of New York Mellon Corp (1.05%), Connor Clark & Lunn Investment Management Ltd. (0.45%), Rhumbline Advisers (0.26%), New York State Teachers Retirement System (0.14%) and New York State Common Retirement Fund (0.09%). Company insiders that own Endo International stock include Nancy J Hutson, Roger H Kimmel and William P Montague. View Institutional Ownership Trends for Endo International.
Which institutional investors are selling Endo International stock?
ENDP stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., Panagora Asset Management Inc., Connor Clark & Lunn Investment Management Ltd., Pinebridge Investments L.P., Arizona State Retirement System, UBS Asset Management Americas Inc., Nisa Investment Advisors LLC and Mitsubishi UFJ Trust & Banking Corp. View Insider Buying and Selling for Endo International.
Which institutional investors are buying Endo International stock?
ENDP stock was bought by a variety of institutional investors in the last quarter, including Dupont Capital Management Corp, Geode Capital Management LLC, Rhumbline Advisers, Sowell Financial Services LLC, 361 Capital LLC and Bank of New York Mellon Corp. View Insider Buying and Selling for Endo International.
How do I buy shares of Endo International?
Shares of ENDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Endo International's stock price today?
One share of ENDP stock can currently be purchased for approximately $6.07.
How big of a company is Endo International?
Endo International has a market capitalization of $1.38 billion and generates $2.95 billion in revenue each year. The company earns $-1,031,470,000.00 in net income (profit) each year or $2.89 on an earnings per share basis. Endo International employs 2,910 workers across the globe.View Additional Information About Endo International.
What is Endo International's official website?
How can I contact Endo International?
Endo International's mailing address is First Floor Minerva House Simmonscourt Road Ballsbridge, Dublin L2, 19355. The company can be reached via phone at 011-353-1268-2000 or via email at [email protected]
MarketBeat Community Rating for Endo International (NASDAQ ENDP)
MarketBeat's community ratings are surveys of what our community members think about Endo International and other stocks. Vote "Outperform" if you believe ENDP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENDP will underperform the S&P 500 over the long term. You may vote once every thirty days.
